News
3h
Zacks.com on MSNMerck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...
18h
Dealbreaker on MSNMerck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona PharmaVerona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
Fintel reports that on July 10, 2025, Wells Fargo downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...
17h
Medpage Today on MSNStudy Sheds New Light on Gabapentin RisksGabapentin is approved for seizures and post-herpetic neuralgia; gabapentin enacarbil is approved for restless legs syndrome.
The Big Beautiful Bill threatens our most vulnerable residents and endangers Baltimore’s recovery. Our city’s renaissance depends on accessible health care, and Baltimore will fight for legislation ...
Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...
Objectives The association between smoking and patients with schizophrenia has been established through epidemiological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results